VetrixBio is now Vetarys. The new corporate name reflects the company’s continued evolution and long-term vision for advancing therapies for companion animals. The name Vetarys is inspired by two roots within the Latin veterinarius: veterinus, meaning “care of animals” and arius, meaning “dedicated to”. It reflects the science, expertise, and innovation that have defined the company and appropriately positions Vetarys for its next stage of growth. The company’s leadership, mission, and pipeline remain unchanged.
Vetarys is a biotechnology company focused on developing novel biologic therapies for companion animals. Guided by the belief that pets deserve better medicine, the company is advancing a pipeline targeting osteoarthritis and cancer—two of the most significant unmet needs in veterinary medicine. Vetarys’s approach centers on translating advances in biologics and immunotherapy into practical treatments designed to improve outcomes and quality of life for dogs and cats. Led by an experienced team spanning biotechnology, animal health, and commercialization, and supported by a network of scientific and clinical advisors, Vetarys is committed to bringing the next generation of veterinary medicines to market.
Vetarys, Inc.
9 Centennial Drive
2nd Floor, Suite 6832
Peabody, MA 01960
info@vetarys.com
This press release contains forward-looking statements, including statements regarding the development, potential efficacy, and future progress of Vetarys’s product candidates. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Vetarys undertakes no obligation to update these statements except as required by law.
